Clinical trials: Non-Diabetic
Non-alcoholic Fatty Liver Disease
Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease
The aim of study was to evaluate the effect of helicobacter pylori eradication on liver fat content, liver function tests, lipid profile, homeostasis model assessment-IR (HOMA-IR) index, and anthropometric measurements (body mass…
- Trial name
- NCT01712711
- Testing
- H.pylori eradication
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Tehran University of Medical Sciences
Diabetic Macular Edema
Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center Involvement
This study evaluated the safety and efficacy of ranibizumab on retinal edema and visual acuity in patients with diabetic macular edema with center involvement.
- Trial name
- RESOLVE (NCT00284050)
- Testing
- Ranibizumab 0.3 mg, Ranibizumab 0.5 mg
- Where
- Switzerland
- Volunteers
- 151 people
- Sponsor
- Novartis
Diabetes
Investigation Into the Effects of Blood Glucose Levels Upon Eating Behavior in Lean and Obese Non-diabetic and Diabetic Subjects
To investigate whether the daily glucose profiles as assessed by continuous glucose monitoring for 1 week of normal weight and obese individuals relate to hunger levels and food intake.
- Trial name
- NCT02673203
- Testing
- Continuous Glucose Monitoring System (CGMS), Food log
- Where
- 2 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Yale University
Proliferative Diabetic Retinopathy
Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy
The RECOVERY trial will assess the safety and tolerability of 2 mg intravitreal aflibercept injections (IAI) given monthly (Q4WK) or every 12 weeks (Q12WK) for the treatment of retinal capillary non-perfusion (RNP) associated…
- Trial name
- RECOVERY (NCT02863354)
- Testing
- Aflibercept
- Where
- 4 sites in United States
- Volunteers
- 43 people
- Sponsor
- Charles C Wykoff, PhD, MD
Obesity, Metabolic Disease
Effects of Colchicine in Non-Diabetic Adults With Metabolic Syndrome
Background: Being overweight may cause low-level inflammation. This inflammation may cause some of the medical problems of obesity, like high blood sugar (diabetes) and heart disease.
- Trial name
- NCT02153983
- Testing
- Colchicine 0.6Mg Cap, Colchicine 0.6Mg Tab
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Type 2 Diabetes
Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates
The gut hormone glucagon like peptide-1 (GLP-1) has been shown to have important effects on maintaining the function and health of the insulin producing beta cells.
- Trial name
- NCT00609154
- Testing
- glucagon like peptide-1, glucose control
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Albert Einstein College of Medicine
Nonproliferative Diabetic Retinopathy
The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
The purpose of this study is to evaluate the safety and efficacy of subcutaneously administered AKB-9778 15mg once daily or 15mg twice daily for 12 months in patients with moderate to severe non-proliferative diabetic retinopathy…
- Trial name
- TIME-2b (NCT03197870)
- Testing
- AKB-9778
- Where
- 53 sites in United States
- Volunteers
- 167 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Type 2 Diabetes Mellitus
Rosiglitazone-Metformin Combination Versus Metformin-Sulfonylurea Combination On Beta-Cell Function In Type 2 Diabetes
It has been shown in previous study that progressive glycemic deterioration was associated with progressive loss of b-cell function, measured by the decrease in plasma insulin levels, irrespective of the therapy used (diet…
- Trial name
- NCT00367055
- Testing
- rosiglitazone-metformin, Metformin, metformin+ gliclazide
- Volunteers
- 84 people
- Sponsor
- GlaxoSmithKline
Diabetic Foot Ulcer
Clinical Investigation of Galnobax® for the Treatment of Diabetic Foot Ulcers
The purpose of this study is to determine safety and efficacy of a new gel formulation of Esmolol hydrochloride (Galnobax®) for the treatment of Diabetic Foot Ulcer (DFU).
- Trial name
- NCT01113515
- Testing
- Esmolol hydrochloride
- Where
- 5 sites in United States, India and 1 more
- Volunteers
- 44 people
- Sponsor
- Novalead Pharma Private Limited
Adenocarcinoma of the Endometrium
A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women
The purpose of this research is to determine the effects of Metformin, a well tolerated drug widely prescribed for treatment of Type 2 Diabetes Mellitus, on endometrium cancer patients.
- Trial name
- NCT01877564
- Testing
- Metformin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Arkansas
Diabetes, Diabetes Mellitus, Type 2
Evaluation of the Glycaemic Control With Insulin Detemir as an add-on to Current Oral Anti-diabetic Drug Treatment in Subjects With Type 2 Diabetes in Korea
This trial is conducted in Asia. This trial aims for evaluating the glycaemic control, measured as glycosylated haemoglobin (Hb1Ac), of once daily insulin detemir as an add-on to oral antidiabetic drug (OAD) in subjects with type…
- Trial name
- NCT00455858
- Testing
- insulin detemir
- Where
- South Korea
- Volunteers
- 87 people
- Sponsor
- Novo Nordisk A/S
Hyperlipidemia
Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease
The purpose of this study is to evaluate the effects of Crestor (rosuvastatin) and (Lipitor) atorvastatin on urinary protein excretion over 1 year in non-diabetes with moderate proteinuria and hypercholesterolaemia.
- Trial name
- PLANET II (NCT00296400)
- Testing
- Rosuvastatin, Atorvastatin
- Where
- 107 sites in United States, Brazil and 9 more
- Volunteers
- 237 people
- Sponsor
- AstraZeneca
Diabetic Retinopathy
HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia
This is a study in people with a type of diabetic eye disease called diabetic retinopathy with diabetic macular ischemia. People who have had laser treatment for their diabetic retinopathy can participate in the study.
- Trial name
- HORNBILL (NCT04424290)
- Testing
- BI 764524
- Where
- 19 sites in United States, United Kingdom
- Volunteers
- 45 people
- Sponsor
- Boehringer Ingelheim
Diabetic Foot Ulcer
Study of Oasis Ultra in Diabetic Foot Ulcers
Many people with diabetes will develop a non-healing diabetic foot ulcer. Many ways are available to try to get a diabetic foot ulcer to heal, including application of Oasis Ultra.
- Trial name
- NCT01835379
- Testing
- Oasis, Standard
- Where
- 16 sites in United States
- Volunteers
- 82 people
- Sponsor
- Healthpoint
Type 2 Diabetes Mellitus
Memory Aid by Intranasal Insulin in Diabetes (MemAID)
The main purpose of this study is to find the long-term effects of daily administration of 40 IU of intranasal insulin (INI) as compared to placebo (sterile saline) on cognition and memory in people with type 2 diabetes mellitus…
- Trial name
- MemAID (NCT02415556)
- Testing
- Regular Human Insulin
- Where
- 2 sites in United States
- Volunteers
- 289 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Kidney Failure, Chronic, Eye Diseases
Feasibility Study of Retinal Screening Using the RetinaVue 100 Camera in Outpatient Dialysis Centers
The purpose of this research study is to look at retinal abnormalities in outpatient renal dialysis patients using the FDA approved RetinaVue 100 hand-held (non-mydriatic) camera.
- Conditions
- Kidney Failure, Chronic, Eye Diseases, Diabetic Retinopathy
- Trial name
- NCT02823600
- Testing
- RetinaVue 100 camera
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of North Carolina, Chapel Hill
Chronic Diabetic Foot Ulcers, Diabetic Neuropathic Ulcers
Beta Adrenergic Antagonist for the Healing of Chronic DFU
One in four Veterans is affected by diabetes and will develop a diabetic foot ulcer. Diabetic ulcers are very challenging to manage and are the most common cause of leg amputation.
- Conditions
- Chronic Diabetic Foot Ulcers, Diabetic Neuropathic Ulcers, Non Healing Wound
- Trial name
- BAART-DFU (NCT03282981)
- Testing
- Timolol, Non biologically active gel
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- VA Office of Research and Development
Non-Proliferative Diabetic Retinopathy, Cataract
Nepafenac Once Daily for Macular Edema - Study 2
The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension, 0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among diabetic participants following cataract surgery.
- Trial name
- NCT01872611
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Vehicle, Prednisolone acetate
- Volunteers
- 819 people
- Sponsor
- Alcon Research
Edema
Mild Compression Sock for Control of Lower Extremity Edema in Individuals With Diabetes
The purpose of this study is to determine whether a specially designed sock for people with diabetes and swelling in the legs can reduce the swelling, improve blood flow to the legs, and improve physical activity patterns of…
- Trial name
- NCT01529385
- Testing
- mild compression diabetic sock, Standard diabetic sock
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Rosalind Franklin University of Medicine and Science
Diabetes, Foot Ulcers
Evaluation of Negative Pressure Wound Therapy in the Treatment of DFUs Incl. Post Amputation Wounds.
Primary objective To assess wound healing and granulation tissue formation when using the NPWT system Secondary objectives To investigate the pain level at dressing removal To visually check exudate removal To investigate the…
- Trial name
- NCT01011387
- Testing
- NPWT System
- Where
- 2 sites in United Kingdom
- Volunteers
- 16 people
- Sponsor
- Molnlycke Health Care AB